SIV/HIV-1 Hybrid Virus Expressing the Reverse Transcriptase Gene of HIV-1 Remains Sensitive to HIV-1-Specific Reverse Transcriptase Inhibitors After Passage in Rhesus Macaques
- 1 May 1997
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 15 (1) , 1-4
- https://doi.org/10.1097/00042560-199705010-00001
Abstract
We have previously described an animal model for the therapy of human immunodeficiency virus type 1 (HIV-1) infection with HIV-1-specific reverse transcriptase(RT) inhibitors based on a simian immunodeficiency virus (SIV), in which the RT gene of SIV was replaced by the RT gene of HIV-1. In vitro, replication of the hybrid virus, RT-SHIV, was delayed compared with parental SIV. RT-SHIV could induce AIDS-like symptoms and pathologic alterations in rhesus macaques. Characterization of re-isolates recovered from RT-SHIV-infected macaques one-half year after infection revealed that the re-isolates replicated with kinetics similar to those of SIV. Inefficient processing of the Gag-Pol precursor of RT-SHIV may be one reason for the retarded growth of RT-SHIV, because the protease cleavage site between the protease gene and the RT gene was frequently mutated in the RT-SHIV re-isolates. Adaptation of RT-SHIV to the growth in macaques did not result in a relevant loss of sensitivity to nonnucleoside RT inhibitors (NNRTIs). However, because a minor subpopulation of the RT-SHIV re-isolates contained a mutation conferring low-level resistance to ddI and ddC, the RT-SHIV/macaque model may underestimate the efficacy of these drugs. Nevertheless, this report further supports the suitability, reliability, and usefulness of the RT-SHIV/macaque model to investigate the antiviral properties of most RT inhibitors in an in vivo setting.Keywords
This publication has 8 references indexed in Scilit:
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: Strategies to overcome drug resistance developmentMedicinal Research Reviews, 1996
- Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.Proceedings of the National Academy of Sciences, 1995
- Sensitivity/Resistance Profile of a Simian Immunodeficiency Virus Containing the Reverse Transcriptase Gene of Human Immunodeficiency Virus Type 1 (HIV-1) Toward the HIV-1-Specific Non-nucleoside Reverse Transcriptase InhibitorsBiochemical and Biophysical Research Communications, 1995
- Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives).Proceedings of the National Academy of Sciences, 1995
- pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivoAntimicrobial Agents and Chemotherapy, 1993
- Directional cloning of PCR products using exonuclease IIINucleic Acids Research, 1992
- Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse TranscriptaseScience, 1991
- The Complete Nucleotide Sequence of a Pathogenic Molecular Clone of Simian Immunodeficiency VirusAIDS Research and Human Retroviruses, 1990